News & Events
12/12/2022
XII ALL-RUSSIAN CONGRESS OF TRAUMATOLOGISTS AND ORTHOPEDISTS
On December 1-3, 2022, the XII All-Russian Congress of Traumatologists and Orthopedists was held, organized by the Association of Traumatologists and Orthopedists of Russia and the Federal State Budgetary Institution “N.M. N.N. Priorov" of the Ministry of Health of Russia. The congress is…
10/12/2022
International Congress of Traumatologists and Orthopedists "Artromost 2022"
On November 26, 2022, Fidia Russia took part in the International Congress of Traumatologists and Orthopedists "Artromost 2022". More than 200 traumatologists from Russian cities, as well as foreign colleagues attended the event. The products of Fidia Pharma, a leader in the development and…
04/07/2022
VI International Congress of the Rheumatic Orthopedics Association
On July 17-18, 2022, Fidia Russia took part in the VI International Congress of the Association of Rheumo-Orthopedists. The event was held in a combined format: face-to-face format with online broadcast. Over 1000 specialists attended the event in 2 days (in person and online) As part of the event,…
21/04/2022
III Congress of Orthobiology 2022 "From research to clinical practice"
On April 15-16, 2022, Fidia Russia took part in the III Congress of Orthobiology 2022 "From research to clinical practice" The event was held in face-to-face format. For 2 days, the event was attended by 400 specialists. Within the framework of the session "Regenerative technologies in…
25/03/2022
VI International School of Association "ARTROMASTER"
On March 18-19, 2022, Fidia Russia took part in the VI International School of the Association "ARTROMASTER", which was held in Kazan. Over 2 days, the event was attended by 250 traumatologists from Russian cities, as well as foreign colleagues. At the Fidia booth, doctors received the latest…
03/11/2021
Scientific and practical conference with international participation "Vredenov readings"
On October 28-29, 2021, Fidia Russia took part in the scientific-practical conference with international participation "Vredenov Readings" The event was held in a combined format: face-to-face with online broadcast Over 2 days, the event was attended by more than 4,000 specialists (in person and…
01/11/2021
Fidia celebrates its 75th anniversary: not a destination, but just one leg of a journey that is going faster than ever
Every day we proudly celebrate the foresight and expertise of those who have helped to build the company, and recognize the vision of those who are already shaping the tomorrow’s world
Founded in 1946, Fidia is celebrating its 75th anniversary with a theme of “Ready for the Future”. This momentous occasion is represented by an image of a tree with solid roots, growing and reaching toward the sky. For us, this anniversary is not a destination, but one leg of a journey that is…
30/10/2021
Distance learning webinar project
Dear partners, Fidia Russia is launching a project of distance learning webinars. This project is aimed at first-table workers. During the webinars, everyone will receive a selection of materials on the company's drugs and will be able to ask questions of interest to specialists. If you want to take…
06/10/2021
V International Congress of the Rheumatic Orthopedics Association
On September 17-18, 2021, Fidia Russia took part in the V International Congress of the Rheumatic Orthopedics Association. The event was held in a combined format: face-to-face format with online broadcast. For 2 days, the event was attended by about 1000 specialists (in person and online). Within…
26/07/2021
Fidia announces the FDA Orphan Drug designation for ONCOFID for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos
Preclinical studies are underway to complete the pharmaco-toxicological profile, with the aim of submitting the authorisation dossier for human studies to the regulatory authorities by 2022.
Abano Terme (PD), July 26th, 2021 - Fidia Farmaceutici, an Italian company world leader in the research, development, formulation and commercialization of hyaluronic acid-based products, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for ONCOFID-P for…
